Proteopathy: The next therapeutic frontier?

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 782-787

  Walker, Lary C ^a   LeVine III, Harry ^a  

^a PFIZER INC   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid; Conformational disease; Creutzfeldt Jakob disease; Dementia; Diabetes; Huntington's disease; Parkinson's disease; Prion; Proteopathy; Synuclein; Tau

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRION PROTEIN;

ACTIVE IMMUNIZATION; AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; ENZYME INHIBITION; GENE MUTATION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; INHERITANCE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOLOGICAL ANATOMY; PRION DISEASE; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN INDUCTION; PROTEIN POLYMERIZATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; PROTEOPATHY; REVIEW; TISSUE INJURY;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEINS;

EID: 0036591266     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Eaton WA, Hofrichter J: The biophysics of sickle cell hydroxyurea therapy. Science (1995) 268:1142-1143.
2. Kakizuka A: Protein precipitation: A common etiology in neurodegenerative disorders? Trends Genet (1998) 14:396-402.
3. Carrell RW, Lomas DA: Conformational disease. Lancet (1997) 350:134-138.
4. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci (1997) 20:154-159.
5. Lansbury Jr PT: Structural neurology: Are seeds at the root of neuronal degeneration? Neuron (1997) 19:1151-1154.
6. Westermark P: Classification of amyloid fibril proteins and their precursors: An ongoing discussion. Amyloid: Int J Exp Clin Invest (1997) 4:216-218.
7. Dobson CM: Protein misfolding, evolution and disease. Trends Biol Sci (1999) 24:329-332.
8. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes (1999) 48:241-253.
9. Koo EH, Lansbury Jr PT, Kelly JW: Amyloid diseases: Abnormal protein aggregation in neurogeneration. Proc Natl Acad Sci USA (1999) 96:9989-9990.
10. Tolnay M, Probst A: Tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol (1999) 25:171-187. Tau is also found in Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Disorders with filamentous neuronal inclusions can be grouped into our categories: taupathies, α-synucleinopathies, polyglutamine disorders (eg, Huntington's disease) and ubiquitin disorders.
11. Hu BR, Martone ME, Jones YZ, Liu CL: Protein aggregation after transient cerebral ischemia. J Neurosci (2000) 20:3191-3199.
12. Walker LC, LeVine III H: The cerebral proteopathies: Neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol (2000) 21:83-95.
13. Walker LC, LeVine III H: The cerebral proteopathies. Neurobiol Aging (2000) 21:559-561.
14. Lee V-Y, Goedert M, Trojanowski J: Neurodegenerative tauopathies. Ann Rev Neurosci (2001) 24:1121-1159.
15. Goebel HH, Warlo I: Gene-related protein surplus myopathies. Mol Genet Metab (2000) 71:267-275.
16. Hoeppener JWM, Ahren B, Lips CJM: Islet amyloid and type 2 diabetes mellitus. New Engl J Med (2000) 343:411-419.
17. Bowen DM, Smith CB, White P, Davison AN: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain (1976) 99:459-496.
18. Davies P, Maloney AJ: Selective loss of cholinergic neurons in Alzheimer's disease. Lancet (1976) 2:1403.
19. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science (1982) 215:1237-1239. Over 75% of neurons in the nucleus basalis of Meynert, the major source of cholinergic innervation of the cerebral cortex, undergo degeneration in AD patients.
20. Bartus R: On neurodegnerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol (2000) 163:495-529.
21. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry (1999) 66:137-147.
22. Grutzendler J, Morris J: Cholinesterase inhibitors and Alzheimer's disease. Drugs (2001) 61:41-52.
23. Knopman DS: Management of cognition and function: New results from the clinical trials programme of Aricept® (donepezil HCl). Int J Neuropsychopharmacol (2000) 3:13-20.
24. Selkoe DJ: Biology of β-amyloid precursor protein and the mechanism of Alzheimer disease. In: Alzheimer Disease, Terry RD, Katzman R, Bick KL, Sisodia SS (Eds). Lippincott Williams and Wilkins, PA, USA (1999):293-310.
25. Worster-Drought C, Hill TR, McMenemey WH: Familial presenile dementia with spastic paralysis. J Neurol Psychopathol (1933) 14:27-34.
26. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J: A stop-codon mutation in the BRI gene associated with familial British dementia. Nature (1999) 399:776-781.
27. Davis RL, Shrimpton AE, Holohan PD, Bradshaw C, Feiglin D, Collins GH, Sonderegger P, Kinter J, Becker LM, Lacbawan F, Krasnewich D, Muencke M, Lawrence DA, Yerby MS, Shaw C-M, Gooptu B, Elliott PR, Finch JT, Carrell RW, Lomas DA: Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 401:376-379.
28. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A: Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet (1996) 13:196-202.
29. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA: Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis (1998) 4:387-397.
30. Gajdusek DC: Spontaneous generation of infectious nucleating amyloids in the transmissible and nontransmissible cerebral amyloidoses. Mol Neurobiol (1994) 8:1-13.
31. DeArmond SJ, Prusiner SB: Etiology and pathogenesis of prion diseases. Am J Pathol (1995) 146:785-811.
32. Aguzzi A, Weissmann C: Prion research: The next frontiers. Nature (1997) 389:795-798.
33. Prusiner SB, Safar J, Cohen FE, De Armond SJ: The prion diseases. In: Alzheimer Disease, Terry RD, Katzman R, Bick KL, Sisodia SS (Eds). Lippincott Williams and Wilkins, PA, USA (1999):161-179.
34. Davis J, Chisholm J: The 'amyloid cascade hypothesis' of AD: Decoy or real McCoy? Trends Neurosci (1997) 20:154-159.
35. Joseph J, Shykitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA: Copernicus revisited: Amyloid β in Alzheimer's disease. Neurobiol Aging (2001) 22:131-146.
36. Terry R: An honorable compromise regarding amyloid in Alzheimer disease. Ann Neurol (2001) 49:684.
37. Wittmann C, Wszolek M, Shulman J, Salvaterra P, Lewis J, Hutton M, Feany M: Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science (2001) 293:711-714. A genetic model of tau-related disease was induced in Drosophila through the expression of mutant forms of human tau. The flies displayed the main features of tauopathies but did not form neurofibrillary tangles.
38. Lorenzo A, Yankner B: β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA (1994) 91:12243-12247.
39. Geula C, Wu C, Saroff D, Lorenzo A, Yuan M, Yankner B: Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med (1998) 4:827-831.
40. Götz J, Chen F, Van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science (2001) 293:1491-1495.
41. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J: Soluble amyloid β-peptide concentration as a predictor of synaptic change in Azheimer's disease. Am J Pathol (1999) 155:853-862.
42. Hsia A, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu K, Kholodenko D, Malenka R, Nicoll R, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA (1999) 96:3228-3233.
43. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Van Den Haute C, Checler F, Godaux E, Cordell B, Van Leuven F: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem (1999) 274:6483-6492.
44. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush A I, Masters CL: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 46:860-866.
45. Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L: High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci (2000) 20:4050-4058.
46. El-Agnaf O, Nagala S, Patel B, Austen B: Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol (2001) 310:157-168.
47. Mucke L, Yu G, McConlogue L, Rockenstein E, Abraham C, Masliah E: Astroglial expression of human α(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol (2000) 157:2003-2010.
48. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA (1998) 95:6448-6453.
49. Volles M, Lee S-J, Rochet J-C, Shtilerman M, Ding T, Kessler J, Lansbury P: Vesicle permeabilization by protofibrillar αsynuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 40:7812-7819.
50. Conway KA, Rochet J-C, Bieganski RM, Lansbury PT: Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science (2001) 294:1346-1349
51. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes (1999) 48:491-498.
52. Harroun T, Bradshaw J, Ashley R: Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Letters (2001) 507:200-204.
53. Arispe N, Pollard H, Rojas E: Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [AβP-(1-40)] in bilayer membranes. Proc Natl Acad Sci USA (1993) 90:10573-10577.
54. Mirzabekov T, Lin M-C, Kagan B: Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem (1966) 271:1988-1992.
55. 2+-sensitive channel in reconstituted lipid vesicles. Biochemistry (1999) 38:11189-11196.
56. Kawahara M, Kuroda Y, Arispe N, Rojas E: Alzheimer's β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem (2000) 275:14077-14083.
57. Hirakura Y, Yiu WW, Yamamoto A, Kagan BL: Amyloid peptide channels: Blockade by zinc and inhibition by Congo red (amyloid channel block). Amyloid (2000) 7:194-199.
58. Hafner J, Cheung C-L, Woolley A, Lieber C: Structural and functional imaging with carbon nanotube AFM probes. Prog Biophys Mol Biol (2001) 77:73-110.
59. Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G: Amyloid β-protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Com Neurol (1998) 397:139-147.
60. Mueller HT, Borg J-P, Margolis B, Turner RS: Modulation of amyloid precursor protein metabolism by X11α/Mint-1. J Biol Chem (2000) 275:39302-39306.
61. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB: Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenillin-1 requires APP. Nature (2001) 414:643-648.
62. Cao X, Suedhof TC: A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science (2001) 293:115-120.
63. Kimberly WT, Zheng JB, Guennette SY, Selkoe DJ: The intracellular domain of the β-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a Notch-like manner. J Biol Chem (2001) 276:40288-40292.
64. Cupers P, Orlans I, Craessaerts K, Annaert W, DeStrooper B: The amyloid precursor protein (APP)-cytoplasmic fragment generated by γ-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J Neurochem (2001) 78:1168-1178.
65. Jin L-W, Hearn MG, Ogburn CE, Dang N, Nochlin D, Ladiges WC, Martin GM: Transgenic mice over-expressing the C-99 fragment of βPP with an α-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol (1998) 153:1679-1686.
66. Askanas V, Engel WK: Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol (2001) 60:1-14.
67. Reiss C, Lesnik T, Parvez H, Parvez S, Ehrlich R: Conformational toxicity and sporadic conformational diseases. Toxicology (2000) 153:115-121.
68. Arriagada PV, Growdon JH, Hedley-Whyte T, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1998) 42:631-639.
69. Berg L, McKeel DW, Miller JF, Baty J, Morris JC: Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol (1993) 50:349-358.
70. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev (2000) 33:95-130.
71. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F: Alzheimer-type neuropathology in transgenic mice. Nature (1995) 373:523-527.
72. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99-102.
73. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Misti C, Rothacher S, Ledermann B, Bürki K, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA (1997) 94:13287-13292.
74. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301) tau protein. Nat Genet (2000) 25:402-405. Transgenic mice displayed motor and behavioral deficits and their brains contained neurofibrillary tangle-like lesions; these occured in hemizygous mice from 6.5 months, and in homozygous mice from 4.5 months.
75. Lewis J, Dickson D, Lin W-L, Chisholm L, Corral A, Jones G, Yen S-H, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 293:1487-1491.
76. Busciglio J, Lorenzo A, Yeh J, Yankner B: β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 14:879-888.
77. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L: β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA (2001) 98:12245-12250.
78. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ: Induction of β (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol (1994) 8:25-39.
79. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC: Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice. J Neurosci (2000) 20:3606-3611.
80. Nilsson L, Bales K, DiCarlo G, Gordon M, Morgan D, Paul S, Potter H: α-1-antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 21:1444-1451.
81. Wisniewski T, Aucouturier P, Soto C, Frangione B: The prionoses and other conformational disorders. Amyloid (1998) 5:212-224.
82. Sayre L, Smith M, Perry G: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem (2001) 8:721-738.
83. Paxinou E, Chen Q, Weisse M, Giasson B, Norris E, Rueter S, Trojanowski J, Lee V-Y, Ischiropoulos H: Induction of α-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 21:8053-8061.
84. Dobson C, Itzhaki R: Herpes simplex virus type I and Alzheimer's disease. Neurobiol Aging (1999) 20:457-465.
85. Bastian F, Foster J: Spiroplasma sp. 16S rDNA in Creutzfeldt-Jakob disease and scrapie as shown by PCR and DNA sequence analysis. J Neuropathol Exp Neurol (2001) 60:613-620.
86. Balin B, Gerard H, Arking E, Appelt D, Branigan P, Abrams J, Whittum-Hudson J, Hudson A: Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (1998) 187:23-42.
87. Esler W, Wolfe M: A portrait of Alzheimer secretases - New features and familiar faces. Science (2001) 293:1449-1454.
88. Puglielli L, Konopka G, Pack-Chung E, Ingano L, Berezovska O, Hyman B, Chang T, Tanzi R, Kovacs D: Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat Cell Biol (2001) 3:905-912.
89. Fassbender K, Simons M, Bergmann C, Stroick M, Luetjohann D, Keller P, Runz H, Kuehl S, Bertsch T, Von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA (2001) 98:5856-5861.
90. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (2001) 414:212-216.
91. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B: β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med (1998) 4:822-826.
92. Sigurdsson E, Permanne B, Soto C, Wisniewski T, Frangione B: In vivo reversal of amyloid-β lesions in rat brain. J Neuropathol Exp Neurol (2000) 59:11-17.
93. Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schuhardt N, Lehrach H, Wanker EE: Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy. Proc Natl Acad Sci USA (2000) 97:6739-6744.
94. Findeis MA: Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim Biophys Acta (2000) 1502:76-84.
95. Howlett D, Perry A, Godfrey F, Swatton J, Jennings K, Spitzfaden C, Wadsworth H, Wood S, Markwell R: Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans. Biochem J (1999) 340:283-289.
96. Kisilevsky R: Anti-amyloid drugs: Potential in the treatment of diseases associated with aging. Drugs Aging (1996) 8:75-83.
97. Warzok RW, Kessler C, Apel G, Schwarz A, Egensperger R, Schreiber D, Herbst EW, Wolf E, Walther R, Walker LC: Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Assoc Disord (1998) 12:33-39.
98. Norlund MA, Lee JM, Zainelli GM, Muma NA: Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res (1999) 851:154-163.
99. Lesort M, Tucholski J, Miller ML, Johnson GV: Tissue transglutaminase: A possible role in neurodegenerative diseases. Prog Neurobiol (2000) 61:439-463.
100. Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW: Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly. Acta Neuropathol (2000) 100:36-42.
101. Ben-Zvi A, Goloubinoff P: Review: Mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones. J Struct Biol (2001) 135:84-93.
102. Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, Durham HD: Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem (1999) 72:693-699.
103. Johnston JA, Ward CL, Kopito RR: Aggresomes: A cellular response to misfolded proteins. J Cell Biol (1998) 143:1883-1898.
104. Selkoe DJ: Clearing the brain's cobwebs. Neuron (2001) 32:177-180.
105. Hampton RY: ER stress response: Getting the UPR hand on misfolded proteins. Curr Biol (2000) 10:R518-R521.
106. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee H-J, Hama E, Sekine-Aizawa Y, Saido T: Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med (2000) 6:143-150.
107. Vogelgesang S, Cascorbi I, Kroemer H, Schroeder E, Pahnke J, Siegmund W, Keil C, Warzok R, Walker L: Deposition of amyloid is inversely correlated with the expression of P-glycoprotein - Implications on the possibility of prevention of Alzheimer's disease. Acta Neuropathol (2001) 102:545.
108. Walker LC, Price DL, Voytko ML, Schenk DB: Labeling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol (1994) 53:377-383. Three aged monkeys were injected intraventricularly with a monoclonal antibody to β-amyloid; the antibody bound to ∼ 5 to 15% of the amyloid deposits in the cerebral cortex.
109. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177.
110. Frenkel D, Katz O, Solomon B: Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA (2000) 97:11455-11459.
111. Morgan D, Diamond D, Gottschall P, Ugen K, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash G: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982-985.
112. Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S, Chishti M, Horne P, Heslin D, French J, Mount H, Nixon R, Mercken M, Bergeron C, Fraser P, St George-Hyslop P, Westaway D: Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979-982.
113. DeMattos R, Bales K, Cummins D, Dodart J-C, Paul S, Holtzman D: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98:8850-8855.
114. Bacskai B, Kajdasz S, Christie R, Carter C, Games D, Seubert P, Schenk D, Hyman B: Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 7:369-372.
115. Hrncic R, Wall J, Wolfenbarger D, Murphy C, Schell M, Weiss D, Solomon A: Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol (2000) 157:1239-1246.
116. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A: Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 294:178-182.